A meta‐analysis of randomized clinical trials reported there is no reduction in major adverse cardiovascular events (MACE) in patients who receive genotype‐guided antiplatelet therapy, but there is a significant reduction in MACE when including only patients who present with acute coronary syndromes and a significant reduction in myocardial infarction.\cite{Rodr_guez_Gonz_lez_2018}